(factor VIII >5%) with Non-
Threatening Bleeding
previously responsive
treatment is the same as for
with hemophilia A.
with a bleeding disorder
triage
clotting factor if:
eyes or evidence of bleeding in these areas.
following trauma.
adhesive, or steri-strips.
internal bleeding.
severe anemia or volume instability.
Hemophilia B without Inhibitor
• Recombinant factor IX or else the patient's product of
choice.
• Plasma-derived concentrate is a suitable alternative in an
emergency situation when recombinant Factor IX is not
available.
• When bleeding is severe, the appropriate dose of factor IX
is 100-140 units/kg. (This should result in a factor IX level of
80-100%.)
hematologist or a regional hemophilia treatment center
decisions may be more complicated. The care of inhibitor patients should be
inhibitor presents in a life- or limb-threatening scenario, the safest immediate
activated prothrombin complex concentrates (FEIBA) at 75-100 units/kg.* The
response to these therapeutic bypassing agents.
in hemophilia A inhibitor patients on emicizumab prophylaxis as aPCCs may cause
those receiving emicizumab and should be avoided.
anaphylaxis, factor IX-containing products, including FEIBA should be avoided.
